PT2928489T - Composição imunogénica - Google Patents

Composição imunogénica

Info

Publication number: PT2928489T
Authority: PT; Portugal
Prior art keywords: immunogenic composition; immunogenic; composition
Prior art date: 2012-12-05

Application number

PT13801540T

Other languages

English (en)

Inventor

Dominique Glaxosmithkline Biologicals S A Boutriau

Sophie Marie Jeanne Valentine Glaxosmithkline Biologicals S A Germain

Hugues Glaxosmithkline Biologicals S A Wallemacq

Original Assignee

Glaxosmithkline Biologicals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-05

Filing date

2013-12-03

Publication date

2019-05-28

2013-12-03 Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa

2019-05-28 Publication of PT2928489T publication Critical patent/PT2928489T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

PT13801540T 2012-12-05 2013-12-03 Composição imunogénica PT2928489T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB201221875		2012-12-05

Publications (1)

Publication Number	Publication Date
PT2928489T true PT2928489T (pt)	2019-05-28

Family

ID=49724573

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT13801540T PT2928489T (pt)	2012-12-05	2013-12-03	Composição imunogénica
PT191590017T PT3513806T (pt)	2012-12-05	2013-12-03	Composição imunogénica

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT191590017T PT3513806T (pt)	2012-12-05	2013-12-03	Composição imunogénica

Country Status (22)

Country	Link
US (2)	US9694064B2 (pt)
EP (2)	EP2928489B1 (pt)
JP (2)	JP6290918B2 (pt)
CN (2)	CN112807422A (pt)
AR (1)	AR093712A1 (pt)
AU (1)	AU2013354186A1 (pt)
BR (1)	BR112015012841B1 (pt)
CA (1)	CA2893435A1 (pt)
CY (1)	CY1121560T1 (pt)
DK (2)	DK3513806T5 (pt)
ES (2)	ES2721930T3 (pt)
FI (1)	FI3513806T3 (pt)
HR (2)	HRP20230359T1 (pt)
HU (2)	HUE061273T2 (pt)
LT (2)	LT3513806T (pt)
PL (2)	PL3513806T3 (pt)
PT (2)	PT2928489T (pt)
SG (1)	SG11201503861UA (pt)
SI (2)	SI3513806T1 (pt)
TR (1)	TR201905272T4 (pt)
WO (1)	WO2014086787A1 (pt)
ZA (1)	ZA201503927B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2351578T (pt) *	2005-06-27	2017-04-07	Glaxosmithkline Biologicals Sa	Processo para o fabrico de vacinas
AU2011298306B2 (en)	2010-09-03	2017-10-19	Valneva Austria Gmbh	Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
JP5917682B2 (ja)	2011-04-22	2016-05-18	ワイス・エルエルシー	変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
BR122016023101B1 (pt)	2012-10-21	2022-03-22	Pfizer Inc	Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
PT2928489T (pt) *	2012-12-05	2019-05-28	Glaxosmithkline Biologicals Sa	Composição imunogénica
DK3160500T3 (da) *	2014-06-25	2019-11-11	Glaxosmithkline Biologicals Sa	Clostridium difficile immunogen sammensætning
CA2954087C (en) *	2014-07-25	2023-09-19	Biosynth S.R.L.	Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
EP3271375B1 (en)	2015-02-19	2021-02-24	Immune Biosolutions Inc.	Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2017165398A1 (en)	2016-03-21	2017-09-28	Children's Medical Center Corporation	Compositions and methods for inhibiting wnt signaling
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
SG11201908376UA (en) *	2017-03-15	2019-10-30	Novavax Inc	Methods and compositions for inducing immune responses against clostridium difficile
CN107397956A (zh) *	2017-08-08	2017-11-28	南开大学	一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
GB201804092D0 (en) *	2018-03-14	2018-04-25	Imperial Innovations Ltd	Methods and compositions
US10933126B2 (en)	2018-05-03	2021-03-02	The Board Of Regents Of The University Of Oklahoma	Clostridium difficile immunogenic compositions and methods of use
EP4168032A2 (en) *	2020-06-19	2023-04-26	Pfizer Inc.	Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2024160901A1 (en)	2023-02-02	2024-08-08	Glaxosmithkline Biologicals Sa	Immunogenic composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en)	1987-06-05	1990-05-14	Us Health	FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER.
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
EP0382271B1 (en)	1989-02-04	1994-12-21	Akzo Nobel N.V.	Tocols as adjuvant in vaccine
JPH0832638B2 (ja)	1989-05-25	1996-03-29	カイロンコーポレイション	サブミクロン油滴乳剤を含んで成るアジュバント製剤
JP3755890B2 (ja)	1992-06-25	2006-03-15	スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム）	アジュバント含有ワクチン組成物
SG48309A1 (en)	1993-03-23	1998-04-17	Smithkline Beecham Biolog	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
NZ337543A (en)	1994-10-24	2002-06-28	Allergan Inc	Composition comprising avian antitoxin against clostridial neurotoxin protein and method for producing recombinant antitoxin proteins are provided for
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6214341B1 (en)	1997-10-20	2001-04-10	Oravax	Passive immunization against Clostridium difficile disease
US6733760B1 (en) *	1999-04-09	2004-05-11	Techlab, Inc.	Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002542169A (ja)	1999-04-09	2002-12-10	テクラブ，インコーポレイテッド	Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
WO2001073030A2 (en)	2000-03-28	2001-10-04	Diadexus, Inc.	Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) *	2005-03-23	2009-01-29	Glaxosmithkline Biologicals, S.A.	Novel use
TWI457133B (zh) *	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
GB0525321D0 (en) *	2005-12-13	2006-01-18	Glaxosmithkline Biolog Sa	Novel compositions
CA2664619C (en) *	2006-10-12	2012-12-11	Glaxosmithkline Biologicals S.A.	Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
GB0711858D0 (en)	2007-06-19	2007-07-25	Glaxosmithkline Biolog Sa	Vaccine
US9320790B2 (en)	2007-09-14	2016-04-26	Sanofi Pasteur Biologics, Llc	Pharmaceutical compositions containing Clostridium difficile toxoids A and B
PL2271360T3 (pl) *	2008-04-16	2016-03-31	Glaxosmithkline Biologicals Sa	Szczepionka
EP2318515A4 (en) *	2008-08-06	2012-11-14	Emergent Product Dev Uk Ltd	DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
AU2011298306B2 (en) *	2010-09-03	2017-10-19	Valneva Austria Gmbh	Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
ES2968455T3 (es) *	2011-05-27	2024-05-09	Glaxosmithkline Biologicals Sa	Composición inmunogénica
PT2928489T (pt) *	2012-12-05	2019-05-28	Glaxosmithkline Biologicals Sa	Composição imunogénica

2013
- 2013-12-03 PT PT13801540T patent/PT2928489T/pt unknown
- 2013-12-03 HU HUE19159001A patent/HUE061273T2/hu unknown
- 2013-12-03 ES ES13801540T patent/ES2721930T3/es active Active
- 2013-12-03 SI SI201332035T patent/SI3513806T1/sl unknown
- 2013-12-03 LT LTEP19159001.7T patent/LT3513806T/lt unknown
- 2013-12-03 WO PCT/EP2013/075405 patent/WO2014086787A1/en active Application Filing
- 2013-12-03 DK DK19159001.7T patent/DK3513806T5/da active
- 2013-12-03 PL PL19159001.7T patent/PL3513806T3/pl unknown
- 2013-12-03 CN CN202011473000.5A patent/CN112807422A/zh active Pending
- 2013-12-03 CN CN201380063596.3A patent/CN104884081A/zh active Pending
- 2013-12-03 TR TR2019/05272T patent/TR201905272T4/tr unknown
- 2013-12-03 CA CA2893435A patent/CA2893435A1/en active Pending
- 2013-12-03 PT PT191590017T patent/PT3513806T/pt unknown
- 2013-12-03 HU HUE13801540A patent/HUE043091T2/hu unknown
- 2013-12-03 AR ARP130104466A patent/AR093712A1/es unknown
- 2013-12-03 AU AU2013354186A patent/AU2013354186A1/en not_active Abandoned
- 2013-12-03 EP EP13801540.9A patent/EP2928489B1/en active Active
- 2013-12-03 DK DK13801540.9T patent/DK2928489T3/en active
- 2013-12-03 HR HRP20230359TT patent/HRP20230359T1/hr unknown
- 2013-12-03 EP EP19159001.7A patent/EP3513806B1/en active Active
- 2013-12-03 SG SG11201503861UA patent/SG11201503861UA/en unknown
- 2013-12-03 SI SI201331393T patent/SI2928489T1/sl unknown
- 2013-12-03 BR BR112015012841-6A patent/BR112015012841B1/pt active IP Right Grant
- 2013-12-03 LT LTEP13801540.9T patent/LT2928489T/lt unknown
- 2013-12-03 JP JP2015545783A patent/JP6290918B2/ja active Active
- 2013-12-03 US US14/649,940 patent/US9694064B2/en active Active
- 2013-12-03 PL PL13801540T patent/PL2928489T3/pl unknown
- 2013-12-03 ES ES19159001T patent/ES2939307T3/es active Active
- 2013-12-03 FI FIEP19159001.7T patent/FI3513806T3/fi active
2015
- 2015-06-01 ZA ZA2015/03927A patent/ZA201503927B/en unknown
2017
- 2017-05-26 US US15/606,439 patent/US10130694B2/en active Active
2018
- 2018-02-08 JP JP2018020900A patent/JP6626521B2/ja active Active
2019
- 2019-04-16 HR HRP20190711TT patent/HRP20190711T1/hr unknown
- 2019-04-19 CY CY20191100436T patent/CY1121560T1/el unknown

Also Published As

Publication number	Publication date
EP3513806A1 (en)	2019-07-24
HRP20190711T1 (hr)	2019-05-31
CN104884081A (zh)	2015-09-02
PL2928489T3 (pl)	2019-07-31
HRP20230359T1 (hr)	2023-06-09
DK2928489T3 (en)	2019-04-23
CA2893435A1 (en)	2014-06-12
PT3513806T (pt)	2023-03-02
ZA201503927B (en)	2017-11-29
TR201905272T4 (tr)	2019-05-21
CN112807422A (zh)	2021-05-18
DK3513806T3 (da)	2023-02-27
FI3513806T3 (fi)	2023-04-26
JP6290918B2 (ja)	2018-03-07
AR093712A1 (es)	2015-06-17
SI3513806T1 (sl)	2023-04-28
EP2928489B1 (en)	2019-02-27
EP3513806B1 (en)	2023-01-25
US10130694B2 (en)	2018-11-20
SG11201503861UA (en)	2015-06-29
JP2016502551A (ja)	2016-01-28
LT3513806T (lt)	2023-04-11
BR112015012841B1 (pt)	2022-05-03
US20170340719A1 (en)	2017-11-30
EP2928489A1 (en)	2015-10-14
US20150313984A1 (en)	2015-11-05
JP6626521B2 (ja)	2019-12-25
HUE061273T2 (hu)	2023-06-28
HUE043091T2 (hu)	2019-08-28
LT2928489T (lt)	2019-04-10
ES2939307T3 (es)	2023-04-20
JP2018104446A (ja)	2018-07-05
CY1121560T1 (el)	2020-05-29
SI2928489T1 (sl)	2019-05-31
BR112015012841A2 (pt)	2017-09-26
DK3513806T5 (da)	2024-09-02
WO2014086787A1 (en)	2014-06-12
US9694064B2 (en)	2017-07-04
AU2013354186A1 (en)	2014-06-12
ES2721930T3 (es)	2019-08-06
PL3513806T3 (pl)	2023-05-15

Publication	Publication Date	Title
HK1231412A1 (zh)	2017-12-22	免疫原性組合物
ZA201503927B (en)	2017-11-29	Immunogenic composition
SG11201404447WA (en)	2014-08-28	Immunogenic composition
PL2647387T3 (pl)	2016-09-30	Kompozycja szczepionki
IL238079A0 (en)	2015-05-31	Immunogenic preparation
SG11201500979RA (en)	2015-07-30	Immunogenic composition
ME02600B (me)	2017-06-20	Imunogena kompozicija
GB201223342D0 (en)	2013-02-06	Immunogenic composition
GB201218660D0 (en)	2012-11-28	Immunogenic composition
GB201204968D0 (en)	2012-05-02	Immunogenic composition
GB201204851D0 (en)	2012-05-02	Immunogenic composition